The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Welcome to MassDevice’s live coverage of the BioMEDevice 2009 conference and trade show here in Boston. We’ll be posting frequent blog updates from the show, bringing you the latest as it happens from the floor. And, of course, as we do every day we’ll be updating our newswire. Thanks for checking in!
{IMGLEFT:http://www.massdevice.com/sites/default/files/featureArt/biomed_logo_200.jpg}
Brian Johnson
What’s more coveted than a Super Bowl ring, a Pulitzer prize and an Academy Award — rolled up into one?
A mention from Oprah, that’s what.
If you’re like me, and you have a Google Alert set for Eleme (I seriously doubt that, unless you’re Nancy Briefs), you might have noticed an uptick in activity.
That’s because the Merrimack, N.H.-based maker of SmoothShapes, a non-invasive laser treatment that blasts away cellulite, was featured in the May 2009 issue of O. That would, of course, be the official magazine of the Opraverse.
Brad Perriello
You’d think after about 20 years, questions about the efficacy of stents would be settled. You’d be wrong.
Even as players large and small scramble to get the first bioabsorbable product to market, there are conflicting reports about the best way to treat heart disease — devices or drugs?
Science fiction is always a few decades ahead of real life — sometimes more.
Remember those giant vegetables in Woody Allen’s 1973 film Sleeper, or the hover skateboard in Back to the Future II, or Mr Spock‘s razor-sharp sideburns in Star Trek?
A press release just came over the transom that reminds me of something I saw in the nearly-straight-to-video masterpiece Idiocracy.
MEDTRONIC COMPLETES ACQUISITION OF ABLATION FRONTIERS MINNEAPOLIS AND CARLSBAD, CALIF.
– Feb. 6, 2009 – Medtronic, Inc. (NYSE: MDT), today announced it has through an affiliated entity, completed the acquisition of privately held Ablation Frontiers, Inc. Under the terms of the agreement announced Jan. 12, 2009, the transaction includes an initial payment of $225 million plus potential additional payments contingent upon achievement of certain clinical milestones.
